Epigenic Therapeutics

Epigenic Therapeutics is a biotechnology company pioneering epigenetic medicine through its proprietary epigenetic modulation platform. Unlike traditional gene editing that cuts or alters DNA, the company uses nuclease-inactivated dead Cas proteins combined with epi-enzymes to precisely control gene expression without any DNA cutting, nicking, or altering. This approach offers high efficiency in inhibiting targeted gene expression, long-lasting durability from a single-course treatment, favorable safety with no chromosomal abnormalities or off-target effects, and non-viral delivery using optimized lipid nanoparticle (LNP) formulations. The company pipeline includes EPI-003, a first-in-class epigenetic inactivator for chronic hepatitis B treatment, which has received NMPA IND clearance. Founded in 2021 and headquartered in Shanghai, China, Epigenic Therapeutics has raised approximately 12 million through Series A and Series B financing rounds, with backing from Qiming Venture Partners, Orbimed, Morningside, FountainBridge Capital, TigerYeah Capital, TIF, Lapam Capital, and IFSC. The company was also listed in Forbes Asia 100 To Watch 2024.